This trial is evaluating whether 5-Cog will improve 1 primary outcome and 2 other outcomes in patients with Dementia. Measurement will happen over the course of 12 months after the participant is randomized.
This trial requires 1200 total participants across 2 different treatment groups
This trial involves 2 different treatments. 5-Cog is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Dementia cannot be cured and does not necessarily lead to the ending of life. However, life-changing therapies are effective to improve quality of life and decrease the need for hospitalization and long-term care.
In the elderly, dementia is defined by cognitive, behavioural and functional deficits resulting from damage to brain structures that support memory, attention and other cognitive processes. Dementia was the most common form of neuropsychiatric disorder identified in this survey. Patients with dementia who consulted specialist mental health professionals were more likely to be elderly, divorced and diagnosed with depression than those who saw family physicians. All GPs who screened for dementia during consultations did so on their own initiative.
Many signs and symptoms of dementia are similar to signs of depression. The signs of dementia include difficulty thinking, difficulty remembering recent event, lack of interest in past events, not sleeping well, and emotional lability. In the Alzheimer's disease type of dementia, signs commonly include slowing or slowing down in activities of daily living. Dementia is a chronic condition, so signs of the person who is no longer affected can become a challenge to caregivers.
The number of people diagnosed with dementia and probable dementia increased at a rate faster than the population increase in 2004, raising concerns about the future number of new diagnoses and future need for resources. The number of dementia cases will continue to increase in the future, potentially resulting in significant healthcare and social consequences.
Common diagnoses and treatments for dementia vary widely among different countries. Some are widely recognized, including cognitive behavioral therapies and memantine, as well as statins for high cholesterol levels and antihypertensives for high blood pressure. Other therapies are relatively rare or unrecognized.
Dementia can cause dementia, and the signs and symptoms vary between different types. Most of the risk factors for dementia are lifestyle choices, such as insufficiently sleep, unhealthy diet, substance abuse, and lack of physical exercise. Some brain insults to the cells or nerve fibre pathways in the brain can also lead to dementia. Brain surgery or a stroke can also cause dementia or other neuropsychiatric disorders. Most of the risk factors for stroke are lifestyle choices, such as lack of exercise, smoking, and obesity. There is evidence that early detection of dementia can delay the disease, possibly by up to 40% or more in those diagnosed with dementia when compared to those who are diagnosed with the dementia without the first memory loss.
It seems as if the new developments have been slow because of the fact it all was based on the initial idea that the patients do not have to be aware of what has happened, that they see it as a positive thing and can continue the therapy without being frustrated. However, there must be more to 5-cog than only a therapy for dementia. If they have a positive effect they still have the chance to find their own way back to normal activities when the illness has stopped.
We did not find enough evidence to support Coggin’s hypothesis in the context of this study. Further research that uses 5-CSF to investigate associations between neurocognitive ability and neuroanatomy, while accounting for brain volume, genetics, and environmental factors, is warranted.
I have not found any medications or other therapy that would show to be helpful in treating dementia. No medicines are effective yet, and no medicines are FDA approved for the treatment of dementia.
This is the first study comparing 5-cog with age- and sex-matched control subjects using the ADCS-PS and MMSE at baseline. Although preliminary as this was an open-label study, these results show that 5-cog is a useful complementary measure for AD in a clinical sample, and is likely to help to improve the diagnosis in at-risk patients such as those with mild cognitive impairment or who are younger than those typically tested with MMSE.
Elderly people with dementia have poor quality care and little contact with healthcare professionals. Thus, people with dementia have a poor likelihood of participating in clinical trials despite the potentially harmful consequences of not doing so. Healthcare professionals have an important role in informing people with dementia of potential clinical trial opportunities.
5-cog has shown more efficacy than 5-cog on average. The two-week group showed a small improvement of 10.2 to 11.3 points and a larger improvement of 15.1 points on average. The difference between the two studies is not statistically significant.